Monday, April 02, 2018 9:31:45 AM
First quarter 2018 preliminary revenue from sales of BioLife's proprietary CryoStor® and HypoThermosol® biopreservation media products reached $3.8 million, the 11th consecutive quarter of record revenue. This represents 61% growth over the first quarter of 2017 and 22% sequential growth over the fourth quarter of 2017.
Mike Rice, BioLife President & CEO, commented, "Our first quarter of 2018 followed on the theme of strong demand we experienced at the end of 2017. Demand for CryoStor and HypoThermosol, our proprietary, clinical grade biopreservation media products, was driven by the regenerative medicine market segment where revenue nearly doubled over the first quarter of 2017. During the first quarter our domestic and international network of distributors also contributed to the increase in revenue. We also benefitted from certain cell therapy customers that placed safety stock orders which accounted for approximately 10% of total revenue. We're off to a great start to the year and are increasing our previous guidance for 2018 biopreservation media revenue."
Management provides the following update to its financial guidance for 2018:
Biopreservation media revenue is now expected to range between $14.5 million to $15.5 million, representing growth of approximately 32% to 41% over 2017. This is an increase from the Company's previous guidance for 2018 revenue of $13.6 million to $14.7 million, or 25% to 35% growth over 2017.
Gross margin to be between 62% and 64%, up from 61% for 2017.
Operating expenses to range from $9 million to $9.5 million compared with 2017 operating expenses of $7.8 million.
Full year GAAP operating profit with proportional increases in adjusted EBITDA and cash flow from operations.
https://finance.yahoo.com/news/biolife-solutions-announces-preliminary-first-120000935.html
Recent BLFS News
- BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences • PR Newswire (US) • 03/04/2024 01:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:05:54 PM
- BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 02/29/2024 09:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:52:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:51:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:51:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:51:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:51:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:50:58 PM
- BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024 • PR Newswire (US) • 02/20/2024 01:03:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 03:11:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 10:10:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:16:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:30:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:29:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:29:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:29:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:29:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:42:02 PM
- BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue • PR Newswire (US) • 01/08/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:04:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:04:28 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM